Teva Agrees To $420m Securities Settlement For Alleged Price Fixing

Israeli Firm Denies Wrongdoing; Proposed Settlement Requires Final Approval

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.